A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.

被引：0
|
作者：
Papadopoulos, Kyriakos P.
Sahebjam, Solmaz
Kelley, Robin Katie
Tolcher, Anthony W.
Razak, Albiruni R. A.
Patnaik, Amita
Bedard, Philippe L.
Arcos, Rebecca
Adriaens, Lieve
Brownstein, Carrie M.
Lowy, Israel
Gao, Bo
DiCioccio, A. Thomas
Trail, Pamela
Siu, Lillian L.
机构：
[1] START Ctr Canc Care, San Antonio, TX USA
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] South Texas Accelerated Res Therapeut LLC, San Antonio, TX USA
[5] Univ Toronto, Dept Med, Div Med Oncol & Hematol, Princess Margaret Canc Ctr,Univ Hlth Network, Toronto, ON, Canada
[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
    Gounder, Mrinal M.
    Bauer, Todd M.
    Schwartz, Gary K.
    Weise, Amy M.
    LoRusso, Patricia
    Kumar, Prasanna
    Tao, Ben
    Hong, Ying
    Patel, Parul
    Lu, Yasong
    Lesegretain, Arnaud
    Tirunagaru, Vijaya G.
    Xu, Feng
    Doebele, Robert C.
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (09) : 1714 - +
  • [32] A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors
    Lassen, U.
    Schellens, J. H. M.
    Siu, L. L.
    Jonker, D. J.
    Sorensen, M.
    Jarutat, T.
    Wang, K.
    Gehoe, D.
    DeMario, M.
    Goss, G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 12 - 12
  • [33] First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
    Berglund, Ake
    Ullen, Anders
    Lisyanskaya, Alla
    Orlov, Sergey
    Hagberg, Hans
    Tholander, Bengt
    Lewensohn, Rolf
    Nygren, Peter
    Spira, Jack
    Harmenberg, Johan
    Jerling, Markus
    Alvfors, Carina
    Ringbom, Magnus
    Nordstrom, Eva
    Soderlind, Karin
    Gullbo, Joachim
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1232 - 1241
  • [34] First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
    Åke Berglund
    Anders Ullén
    Alla Lisyanskaya
    Sergey Orlov
    Hans Hagberg
    Bengt Tholander
    Rolf Lewensohn
    Peter Nygren
    Jack Spira
    Johan Harmenberg
    Markus Jerling
    Carina Alvfors
    Magnus Ringbom
    Eva Nordström
    Karin Söderlind
    Joachim Gullbo
    Investigational New Drugs, 2015, 33 : 1232 - 1241
  • [35] A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.
    Weekes, C. D.
    Hegde, P.
    Xin, Y.
    Yu, R.
    Xiang, H.
    Beeram, M.
    Gore, L.
    Brachmann, R. K.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors
    Sandhu, S. K.
    Fong, P. C.
    Frentzas, S.
    Patnaik, A.
    Papadopoulos, K.
    Tromp, B.
    Puchalski, T.
    Berns, B.
    Tolcher, A. W.
    De-Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] First-in-human, phase I study of AK109, an anti-VEGFR2 antibody, in patients (pts) with advanced or metastatic solid tumors.
    Xu, Nong
    Zheng, Yulong
    Zhong, Haijun
    Zhao, Fuyou
    Zhou, Huan
    Mao, Chenyu
    Lv, Wangxia
    Yuan, Meiqin
    Qian, Jiong
    Jiang, Haiping
    Wang, Zishu
    Xiao, Cheng
    Liu, Ting
    Liu, Wei
    Li, Baiyong
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
    Beatty, Gregory L.
    O'Dwyer, Peter J.
    Clark, Jason
    Shi, Jack G.
    Bowman, Kevin J.
    Scherle, Peggy A.
    Newton, Robert C.
    Schaub, Richard
    Maleski, Janet
    Leopold, Lance
    Gajewski, Thomas F.
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3269 - 3276
  • [40] Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
    Ming-Mo Hou
    Ching-Liang Ho
    Hsuan-Yu Lin
    Yunting Zhu
    Xiaodi Zhang
    Investigational New Drugs, 2021, 39 : 1315 - 1323
12345